NCT06396416View on ClinicalTrials.gov

Obesity Management for Kidney TRANSPLANTation: OK-TRANSPLANT 2

PHASE4RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
ObesityChronic Kidney Disease
Interventions
DRUG

Semaglutide

Maximum tolerated dose of semaglutide subcutaneously once weekly. Maximum dose of 2.0 mg.

BEHAVIORAL

Virtual Weight Management Coaching

Virtual meeting with intervention coach once every 4 weeks for 6 months, where the coach will discuss the goals and progress with participant, nutritional advice, exercise advice, and motivational support.

Trial Locations (1)

N6A 5A5

RECRUITING

London Health Sciences Centre, London

All Listed Sponsors
collaborator

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER

collaborator

Queen Elizabeth II Health Sciences Centre

OTHER

collaborator

St. Michael's Hospital (Toronto, Canada)

UNKNOWN

lead

Western University, Canada

OTHER